View Article

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide, with an escalating global burden. This review comprehensively examines the causes, risk factors, classification systems, and contemporary diagnostic and therapeutic strategies for lung cancer management. The pathogenesis of lung cancer involves critical genetic mutations, environmental exposures, and lifestyle factors, with chronic inflammation playing a pivotal role in disease progression. Modern diagnostic approaches, including liquid biopsies, advanced imaging techniques, and molecular biomarkers, enable earlier detection and more accurate disease characterization. Treatment modalities have evolved significantly, with targeted therapies and immunotherapies providing personalized treatment options alongside conventional approaches. However, substantial challenges persist, including drug resistance, disparities in treatment accessibility, and the need for truly personalized medicine. Emerging innovations such as CRISPR-based gene editing, CAR-NK cell therapy, and artificial intelligence-driven analytics hold promise for further improving patient outcomes. This review emphasizes the critical importance of integrative, patient-centered treatment approaches that prioritize both survival and quality of life, while highlighting the urgent need for continued research and interdisciplinary collaboration in the ongoing battle against lung cancer

Keywords

Lung cancer, Genetic mutations, Diagnosis, Targeted therapy, Immunotherapy, Liquid biopsy, CRISPR, Personalized medicine.

Introduction

Lung cancer represents one of the most significant global health challenges, serving as the primary cause of cancer-related mortality worldwide. In 2020, approximately 2.2 million new cases and 1.8 million deaths were attributed to lung cancer globally, with notable regional and demographic variations [1]. By 2022, these numbers had increased to approximately 2.5 million new cases (representing 1 in 8 diagnosed cancers worldwide) and 1.8 million deaths (accounting for 1 in 5 cancer-related deaths) [2]. Despite substantial therapeutic advances, the prognosis remains challenging, with persistently low survival rates and debilitating symptoms that severely compromise patient quality of life [3].

1.1 Key Characteristics of Lung Cancer's Global Impact

1.1.1 Epidemiological Trends

Lung cancer contributes substantially to the global burden of cancer mortality and disability-adjusted life years (DALYs). Between 2007 and 2017, lung cancer incidence increased by 37%, a rise attributable to changes in age distribution, population growth, and variations in age-specific incidence rates [4]. The age-standardized incidence rate (ASIR) demonstrates marked geographic variation, ranging from 36.8 per 100,000 population in Denmark to 5.9 per 100,000 in Mexico [1]. Males experience approximately twice the burden of females, with the highest impact observed in populations aged 65 years and older [5].

1.1.2 Risk Factors

Multiple factors influence lung cancer risk, with tobacco smoking remaining the predominant cause. Additional contributors include environmental pollution, occupational exposures, and dietary practices [6,7]. While tobacco remains the leading risk factor, tobacco control efforts have achieved partial success in some regions [5]. In OECD countries, occupational carcinogen-attributable lung cancer deaths increased from 120,862 in 1990 to 167,917 in 2019 [8].

1.1.3 Geographical Disparities

Substantial geographic variation in lung cancer burden reflects differences in risk factor prevalence, including smoking rates, environmental pollution levels, and sociodemographic factors. In 2018, a 20-fold difference in incidence and mortality rates existed across regions. Asia accounted for approximately 50% of global lung cancer cases and deaths in 2020 [1,9].

1.1.4 Socio-Demographic Factors and Survival Rates

Lung cancer patterns and determinants vary according to a country's socio-demographic index (SDI), which incorporates income, education, and fertility rates. Despite consistently low 5-year net survival rates globally, some countries have achieved improvements between 1995-1999 and 2000-2014 [4].

1.2 Objectives of the Review

1.2.1 Comprehensive Overview

This review provides thorough analysis of lung cancer, encompassing etiology, risk factors, classification, diagnostic methods, and therapeutic approaches.

1.2.2 Highlight Key Advances

The review explores modern diagnostic techniques, molecular biomarkers, and emerging therapeutic strategies, including targeted therapies and immunotherapy.

1.2.3 Identify Management Challenges

Critical barriers including treatment resistance, drug accessibility disparities, and healthcare delivery challenges are addressed.

1.2.4 Future Research Directions

Innovative approaches including artificial intelligence, big data applications, and novel treatment modalities are examined for their potential to improve patient outcomes.

1.2.5 Emphasize Personalized Medicine

Given lung cancer complexity, the review underscores the importance of individualized treatment plans based on genetic and molecular profiling.

1.2.6 Promote Awareness and Research

By synthesizing current findings, the review aims to enhance understanding among researchers, healthcare professionals, and policymakers, driving continued advancement in lung cancer prevention, diagnosis, and treatment.

1.3 Scope of the Article

This comprehensive review examines lung cancer from etiology through treatment modalities. Beginning with genetic and environmental influences, including chronic inflammation's role, the review analyzes lung cancer subtypes with emphasis on NSCLC and SCLC. Diagnostic approaches including imaging, biomarkers, and liquid biopsies are evaluated alongside standard and novel therapies such as surgery, chemotherapy, targeted therapy, and immunotherapy. The article addresses challenges including drug resistance and treatment accessibility while advocating for personalized medicine approaches. Future opportunities involving big data analytics, artificial intelligence, and integrative care to improve patient outcomes and guide clinical and research directions are explored.

2. CAUSES OF LUNG CANCER

2.1 Genetic Mutations and Molecular Mechanisms

2.1.1 Genetic Mutations in Lung Cancer

Common Mutations: Key genes implicated in lung cancer pathogenesis include TP53, EGFR, ALK, HER2, and KRAS. EGFR and ALK mutations are particularly prevalent in non-small cell lung cancer (NSCLC) and represent critical drivers of carcinogenesis [10].

Familial Patterns: Familial lung cancer syndromes indicate inherited genetic susceptibility factors with increased incidence. Hereditary mutations transmitted through germline cells are present in all body cells and significantly elevate individual lung cancer risk [11].

2.1.2 Molecular Mechanisms

Tumor Suppressor Genes: Loss-of-function mutations in tumor suppressor genes including TP53 and PTEN represent common mechanisms driving tumorigenesis. TP53 gene mutations produce mutant p53 protein unable to bind DNA effectively, thus failing to regulate cell division and allowing DNA damage accumulation. The result is uncontrolled cell division and potential tumor formation [12].

KRAS Mutations: KRAS mutations occur frequently in NSCLC, causing continuous activation of signaling pathways essential for cell growth and survival. These mutations are often associated with resistance development to specific treatments [13].

EGFR Mutations: EGFR gene mutations, including exon 19 deletions and the L858R point mutation in exon 21, cause constitutive receptor activation, driving tumor growth. The T790M mutation in exon 20 confers resistance to EGFR tyrosine kinase inhibitors by enhancing receptor ATP affinity, thereby overcoming inhibitor effects [14].

ROS1 Rearrangements: ROS1 gene rearrangements generate fusion proteins with constitutive kinase activity, promoting oncogenesis. These alterations occur in a subset of NSCLC patients and are targetable with specific therapies [13].

Genomic Instability: Lung cancer exhibits high genomic instability characterized by DNA methylation, point mutations, and chromosomal alterations, which are exacerbated by environmental carcinogen exposure [15].

2.1.3 Environmental and Genetic Interactions

Synergistic Effects: Germline mutations may interact synergistically with environmental factors such as tobacco smoke, amplifying lung cancer risk, particularly in never-smokers [11].

2.2 Environmental and Lifestyle Factors Contributing to Oncogenesis

2.2.1 Environmental Carcinogens

Chemical Exposure: Well-documented carcinogens including asbestos, radon, arsenic, and heavy metals (cadmium, chromium) induce genetic mutations leading to lung cancer [16].

Air Pollution: Airborne particulate pollution from industrial emissions and vehicle exhaust demonstrates strong associations with cancer rates [17,18]. Ambient air pollution, including particulate matter (PM2.5, PM10) and nitrogen dioxide (NO2), increases lung cancer risk. PM2.5 and PM10 increase lung cancer risk by 18% and 22% per 5 µg/m³ and 10 µg/m³ concentration increase, respectively. Environmental pollution may account for 36% of all lung cancer deaths, corresponding to approximately 265,000 annual deaths [19].

Occupational Exposures: Occupational contact with carcinogenic agents including arsenic, asbestos, and diesel engine emissions significantly influences lung cancer risk. Asbestos exposure demonstrates particularly strong associations with both mesothelioma and lung cancer [20].

2.2.2 Lifestyle Factors

Smoking: Tobacco smoking represents the primary risk factor for lung cancer, with clear dose-response relationships between smoking behavior and cancer incidence [18]. Approximately 90% of lung cancers are linked to cigarette smoking, detected in about 80% of cases [19]. Tobacco smoke contains numerous carcinogens causing DNA damage and triggering uncontrolled cell growth. Lung cancer risk correlates with smoking duration and intensity. Passive smoking (secondhand smoke exposure) also elevates lung cancer risk [21].

Vaping: Electronic cigarette proliferation introduces new carcinogenic risks due to harmful compound presence, although long-term effects require further investigation [17].

Vitamin Supplements: Beta-carotene supplementation may increase lung cancer risk, particularly in heavy smokers (≥1 pack daily) who consume alcohol regularly [22].

Diet and Physical Activity: Diet and exercise represent important lung cancer risk modifiers. Fruit and vegetable consumption may reduce risk, while physical activity demonstrates protective effects. Conversely, excessive alcohol consumption may increase lung cancer risk [23].

2.3 The Role of Chronic Inflammation and Infections

Chronic inflammation and infections contribute significantly to lung cancer development by creating microenvironments conducive to tumorigenesis. Multiple studies demonstrate pathways through which chronic inflammation, often infection-mediated, promotes lung cancer progression.

2.3.1 Chronic Inflammation and Cancer Pathogenesis

  • Chronic inflammation contributes to approximately 25% of all cancer cases, while specific environmental factors including smoking and inhaled pollutants implicate 30% of lung cancers [24].
  • Inflammatory responses induce epigenetic changes, increased cell proliferation, and apoptosis resistance, facilitating tumor formation [24,25].
  • Prolonged exposure to pollutants, tobacco smoke, and asbestos fibers triggers cytokine release and growth factor production, promoting mutant cell proliferation [26].
  • Chronic pulmonary inflammatory conditions create environments facilitating tumor initiation and progression; continued carcinogen exposure, including asbestos, leads to conditions such as asbestosis, closely associated with lung cancer [27].

2.3.2 Role of Infections

  • Chronic infections such as Mycobacterium tuberculosis contribute to lung carcinogenesis by inducing chronic inflammation, creating tumor-supportive microenvironments [28].
  • Bacterial infections may recruit immune cells supporting cancer metastasis, with studies demonstrating that chronic pulmonary infections enhance breast cancer lung metastasis [29].
  • Approximately 15-20% of global cancer deaths are attributable to chronic infection and inflammation. Previous lung conditions—chronic bronchitis, emphysema, pneumonia—significantly influence lung cancer risk among non-smokers [30].
  • While infections with parasites such as Schistosoma haematobium and liver flukes (Opisthorchis viverrini, Clonorchis sinensis) are established for other organ cancers, their relationship with lung cancer requires further investigation [31].

2.3.3 Immune Microenvironment Interactions

Chronic inflammation and immune microenvironment interactions are crucial, potentially provoking immune escape and cancer progression, with particular vulnerability to coinfections such as COVID-19 [25,32].

3. LUNG CANCER SPECTRUM

The lung cancer spectrum encompasses multiple biological, genetic, and clinical factors reflecting this condition's complex pathology. Enhanced understanding of this spectrum improves diagnosis, treatment, and patient outcomes, with increasing recognition of epithelial-mesenchymal transition (EMT) dynamics, genetic mutation profiles, and advanced imaging modalities' roles.

3.1 Epithelial-Mesenchymal Transition (EMT)

  • EMT plays significant roles in lung cancer metastasis, with hybrid epithelial-mesenchymal states particularly conducive to tumor spread [33].
  • Stem cells exhibit greater EMT plasticity, enhancing metastatic potential, while non-stem cells demonstrate phenotypic stability [33].

3.2 Genetic Mutation Spectrum

  • Regional studies (e.g., Qujing, Yunnan) reveal prevalent mutations including EGFR, KRAS, and TP53, with significant variations based on gender and lifestyle factors [34].
  • Germline mutations, including BRCA2 and ATM, contribute to lung cancer susceptibility, indicating unique fusion molecular spectra in mutation carriers [35].

3.3 Imaging and Diagnosis

  • Energy-spectrum CT and radiomics emerge as vital tools for non-invasive lung cancer diagnosis and subtype differentiation, enhancing clinical decision-making clarity and information availability [36].

4. CLASSIFICATION OF LUNG CANCER

Lung cancer classification systems have evolved to incorporate histological, molecular, and clinical characteristics, enabling more precise diagnosis and treatment selection.

4.1 Histological Classification

4.1.1 Non-Small Cell Lung Cancer (NSCLC)

NSCLC accounts for approximately 85% of all lung cancers and includes three major subtypes:

Adenocarcinoma:

  • Most common NSCLC subtype (approximately 40% of lung cancers)
  • Typically originates in peripheral lung tissue
  • More common in non-smokers and women
  • Often presents as ground-glass opacities on imaging
  • May exhibit lepidic, acinar, papillary, micropapillary, or solid growth patterns

Squamous Cell Carcinoma:

  • Represents approximately 25-30% of lung cancers
  • Typically arises in central airways
  • Strongly associated with smoking history
  • Characterized by keratinization and intercellular bridges
  • Often presents with central cavitation

Large Cell Carcinoma:

  • Accounts for approximately 10-15% of lung cancers
  • Diagnosis of exclusion when adenocarcinoma or squamous features are absent
  • Typically poorly differentiated
  • Often presents as large peripheral masses
  • Generally associated with poor prognosis

4.1.2 Small Cell Lung Cancer (SCLC)

  • Represents approximately 15% of all lung cancers
  • Characterized by rapid growth and early metastasis
  • Strong association with tobacco smoking
  • Neuroendocrine tumor origin
  • Highly sensitive to chemotherapy and radiation initially, but prone to recurrence
  • Limited stage (confined to one hemithorax) versus extensive stage (beyond one hemithorax)

4.2 Molecular Classification

Modern lung cancer classification increasingly incorporates molecular characteristics:

4.2.1 Actionable Driver Mutations

EGFR Mutations:

  • Present in 10-15% of Western populations, 30-50% of Asian populations
  • Common mutations: exon 19 deletions, L858R point mutation
  • Targetable with EGFR tyrosine kinase inhibitors

ALK Rearrangements:

  • Present in 3-5% of NSCLC cases
  • More common in younger patients and never-smokers
  • Targetable with ALK inhibitors

ROS1 Rearrangements:

  • Present in 1-2% of NSCLC cases
  • Similar patient demographics to ALK-positive cancers
  • Targetable with specific inhibitors

KRAS Mutations:

  • Most common oncogenic driver in lung adenocarcinoma (25-30%)
  • KRAS G12C mutations now targetable with specific inhibitors

BRAF Mutations:

  • Present in 1-3% of NSCLC cases
  • V600E mutation targetable with BRAF inhibitors

MET Alterations:

  • MET exon 14 skipping mutations in 3-4% of NSCLC
  • MET amplification as resistance mechanism
  • Targetable with MET inhibitors

RET Fusions:

  • Present in 1-2% of NSCLC cases
  • More common in never-smokers
  • Targetable with selective RET inhibitors

NTRK Fusions:

  • Rare (<1%) but pan-cancer targetable alterations
  • Highly responsive to TRK inhibitors

4.2.2 Immune Biomarkers

PD-L1 Expression:

  • Tumor proportion score (TPS) guides immunotherapy selection
  • TPS ≥50% indicates potential for single-agent immunotherapy
  • TPS 1-49% may benefit from combination therapy

Tumor Mutational Burden (TMB):

  • High TMB (≥10 mutations/megabase) predicts immunotherapy response
  • Associated with smoking-related cancers

Mismatch Repair Deficiency:

  • Rare in lung cancer but highly predictive of immunotherapy response

4.3 Staging Classification

4.3.1 TNM Staging System (8th Edition)

T (Primary Tumor):

  • Tx: Primary tumor cannot be assessed
  • T0: No evidence of primary tumor
  • Tis: Carcinoma in situ
  • T1: Tumor ≤3 cm (subdivided into T1a, T1b, T1c)
  • T2: Tumor >3 cm but ≤5 cm (subdivided into T2a, T2b)
  • T3: Tumor >5 cm but ≤7 cm or invasion of specific structures
  • T4: Tumor >7 cm or invasion of critical structures

N (Regional Lymph Nodes):

  • N0: No regional lymph node metastasis
  • N1: Metastasis to ipsilateral peribronchial and/or hilar nodes
  • N2: Metastasis to ipsilateral mediastinal and/or subcarinal nodes
  • N3: Metastasis to contralateral or supraclavicular nodes

M (Distant Metastasis):

  • M0: No distant metastasis
  • M1a: Separate tumor nodules in contralateral lung, pleural/pericardial effusion
  • M1b: Single extrathoracic metastasis
  • M1c: Multiple extrathoracic metastases

4.3.2 Stage Groupings

  • Stage 0: Tis N0 M0
  • Stage IA: T1 N0 M0
  • Stage IB: T2a N0 M0
  • Stage IIA: T2b N0 M0
  • Stage IIB: T1-2 N1 M0 or T3 N0 M0
  • Stage IIIA: T1-4 N2 M0 or T3-4 N1 M0
  • Stage IIIB: T1-4 N3 M0 or T4 N2 M0
  • Stage IIIC: T3-4 N3 M0
  • Stage IVA: Any T, Any N, M1a-b
  • Stage IVB: Any T, Any N, M1c

4.4 Clinical Classification

Performance Status:

  • Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status
  • Critical for treatment decision-making and prognosis

Smoking Status:

  • Never-smoker (<100 lifetime cigarettes)
  • Former smoker
  • Current smoker
  • Influences mutation profile and treatment selection

5. MODERN DIAGNOSTIC APPROACHES

5.1 Advances in Imaging Techniques

Advances in modern diagnostic imaging modalities, particularly computed tomography (CT) and positron emission tomography (PET), have substantially enhanced diagnostic efficiency and accuracy. These advances integrate conventional imaging with innovative technologies, improving both anatomical and functional imaging capabilities [37].

5.1.1 Computed Tomography (CT)

CT scanning has evolved substantially, offering speed and precision. Modern CT scanners incorporating multislice detectors enable sophisticated acquisition techniques including coronary CT angiography and 4D CT, facilitating detailed anatomical imaging and functional assessments [37].

5.1.2 Positron Emission Tomography (PET)

PET imaging visualizes functional metabolic processes using radioactive tracers. Applications include oncology, neurology, and cardiology [37].

5.1.3 PET/CT: A Synergistic Approach

PET/CT integration combines anatomical and functional data in a single imaging modality, revolutionizing medical imaging. This hybrid approach provides several advantages over standalone PET or CT [38,39].

5.1.4 Advances in Imaging Techniques

Hybrid Imaging: PET-CT combination has transformed diagnostic imaging by providing anatomical and functional insights, improving lesion detection and treatment response evaluation [40].

AI Integration: Artificial intelligence enhances image analysis, automates tasks, and personalizes protocols, improving diagnostic accuracy and workflow efficiency [41].

Non-invasive Methods: Techniques such as elastography and photoacoustic imaging reduce ionizing radiation reliance, addressing safety concerns associated with conventional imaging [41].

5.1.5 Clinical Applications of PET/CT

Cancer Staging: Determining cancer extent and identifying distant metastases

Treatment Response Monitoring: Evaluating chemotherapy and radiation therapy effectiveness

Recurrence Detection: Identifying recurrent cancer earlier than alternative modalities

Biopsy Guidance: Ensuring sampling of metabolically active tumor regions

Radiation Therapy Planning: Targeting radiation to tumors while sparing healthy tissue

5.2 Molecular Diagnostics and Biomarkers

Molecular diagnostics and biomarker advances enable personalized, highly targeted therapies. These approaches utilize high-throughput techniques and molecular information for accurate disease diagnosis and monitoring. Integration of genomics, proteomics, metabolomics, and transcriptomics is essential for identifying and validating biomarkers for disease profiling and personalized medicine.

5.2.1 High-Throughput Omics Technologies

  • Genomics, proteomics, metabolomics, and transcriptomics enable comprehensive biomarker detection for disease monitoring [42,43].
  • Next-generation sequencing (NGS) and multi-omics approaches provide detailed insights into genetic mutations and disease pathogenesis, particularly for cardiovascular diseases and cancer [43,44].

5.2.2 Biomarker Applications

  • Biomarkers are categorized as diagnostic, prognostic, predictive, and monitoring types, each serving distinct healthcare and environmental research roles [45].
  • In cancer, molecular biomarkers facilitate early detection, treatment selection, and monitoring, with liquid biopsies offering non-invasive diagnostic options [44].
  • Cardiovascular diagnostics benefit from molecular tools assessing risk and personalizing treatment, enhancing patient outcomes [43].

5.2.3 Nucleic Acid-Based Diagnostics

  • These diagnostics detect specific nucleotide sequences to identify genetic variations, crucial for diagnosing inherited and infectious diseases [46].
  • They provide high sensitivity and specificity, essential for personalized medicine and disease predisposition prediction [46].

5.3 Role of Liquid Biopsies in Early Detection and Monitoring

Liquid biopsies represent groundbreaking approaches for non-invasive cancer detection and monitoring. These processes enable tumor characterization and treatment response assessment through analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), providing unique insights into tumor characteristics and treatment responses that enhance personalized medicine approaches.

5.3.1 Early Detection Capabilities

  • Liquid biopsies facilitate earlier cancer identification compared with traditional methods, significantly improving patient outcomes [47].
  • Techniques including digital PCR and advanced cfDNA fragmentomics demonstrate high sensitivity (94%) and specificity (98%) for hepatocellular carcinoma (HCC) detection [47].
  • Machine learning integration with cfDNA analysis enhances accuracy in distinguishing cancerous from precancerous states [47].

5.3.2 Monitoring and Treatment Response

  • Liquid biopsies enable real-time treatment effectiveness evaluation and minimal residual disease (MRD) identification, crucial for treatment regimen adjustments [48].
  • Tumor marker analysis reveals tumor heterogeneity and drug resistance likelihood, facilitating personalized treatment planning [48].

5.3.3 Technological Innovations

  • Recent biosensing technology advances, including optical and electrochemical sensors, have improved liquid biopsy assay detection limits and specificity [49].
  • CRISPR-based methods emerge as innovative approaches for rapid, accurate cancer detection [50].

6. TREATMENT MODALITIES

6.1 Surgical Interventions and Their Advancements

Surgical interventions, particularly for NSCLC, remain cornerstone lung cancer treatments. Recent advancements focus on surgical technique optimization and novel therapy integration to enhance patient outcomes.

6.1.1 Minimally Invasive Techniques

  • Video-assisted thoracic surgery (VATS) and robotic-assisted thoracoscopic surgery (RATS) are increasingly applied for early-stage NSCLC, offering advantages including shorter recovery times and lower complication rates compared with open surgical procedures [51].
  • Sub-lobar resections are performed more frequently, particularly for patients with ground-glass opacities, effectively treating tumors while preserving lung function [51].

6.1.2 Integration of Systemic Therapies

  • Immune checkpoint inhibitors in neoadjuvant and adjuvant settings have transformed resectable NSCLC management, enhancing surgical treatment outcomes [52].
  • Targeted therapies for specific genetic mutations (EGFR, ALK) are increasingly integrated into surgical treatment plans for personalized disease management [53].

6.2 Radiation Therapy Techniques and Effectiveness

Radiation therapy (RT) plays pivotal roles in lung cancer treatment, particularly for unresectable tumors. Recent technological advances and clinical methodologies have prolonged survival with reduced complications. This section discusses major radiation therapy modalities, their efficacy, and recent developments in lung cancer therapy.

6.2.1 Key Radiation Therapy Techniques

Stereotactic Body Radiation Therapy (SBRT): This technique improves local control rates by precisely delivering high radiation doses to tumors with minimal side effects, including radiation pneumonitis [54,55].

Intensity-Modulated Radiation Therapy (IMRT): IMRT delivers varying radiation doses to different tumor regions while sparing surrounding healthy tissue, reducing toxicity [56].

Particle Beam Therapy: Techniques including proton and carbon-ion therapy are gaining prominence, particularly in Japan, for early-stage lung cancer, offering targeted treatment with fewer side effects [54].

6.2.2 Effectiveness of Radiation Therapy

Combination Therapies: RT integration with immunotherapy, particularly immune checkpoint inhibitors, has demonstrated promising results in enhancing overall survival and local control in advanced lung cancer [57].

Technological Advances: Innovations in tumor motion management and imaging have enhanced radiation delivery precision, improving patient outcomes [55,56].

6.3 Chemotherapy Regimens and Their Role in Treatment Plans

Chemotherapy forms a pillar of lung cancer treatment, with combination regimens formulated according to patient characteristics. It is frequently combined with other modalities including targeted therapy and immunotherapy, enhancing overall treatment efficacy.

6.3.1 Types of Lung Cancer and Chemotherapy Protocols

Non-Small Cell Lung Cancer (NSCLC): Commonly used protocols include platinum-based doublets such as cisplatin or carboplatin combined with pemetrexed, paclitaxel, or gemcitabine [58].

Small Cell Lung Cancer (SCLC): SCLC treatment benefits from combination therapies including etoposide with cisplatin or carboplatin, achieving improved survival rates [59].

6.3.2 Role in Treatment Plans

  • Chemotherapy remains essential for patients progressing after targeted therapies or immunotherapies, providing standard-of-care that enhances survival and quality of life [59].
  • Personalized medicine approaches are increasingly integrated, enabling tailored chemotherapy regimens based on genetic and molecular tumor characteristics [60].

6.4 Targeted Therapies

Targeted therapies focusing on specific genetic abnormalities and oncogenic fusions have revolutionized lung cancer treatment approaches, particularly for NSCLC. These treatments, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, target critical pathways including EGFR and ALK, significantly enhancing patient outcomes.

6.4.1 Mechanisms of Action and Specific Targets

 

Target

Mechanism and Clinical Application

Tyrosine Kinase Inhibitors (TKIs) [61]

TKIs are fundamental in NSCLC treatment, targeting EGFR, ALK, and ROS1 mutations. As ATP-competitive, irreversible inhibitors, they block signaling pathways, significantly improving prognosis in first- and second-line therapy for mutation-positive patients.

Monoclonal Antibodies (mAbs) [62,63]

Monoclonal antibodies such as bevacizumab target VEGF to inhibit tumor angiogenesis in NSCLC, though identifying ideal candidates for such therapy remains challenging.

Bispecific Antibodies (BsAbs) [64]

Bispecific antibodies such as amivantamab target both EGFR and MET pathways simultaneously, demonstrating stronger antitumor activity than small-molecule inhibitors and offering promising approaches to overcome resistance in NSCLC.

Antibody-Drug Conjugates (ADCs) [65]

ADCs deliver chemotherapy directly to tumor cells via monoclonal antibodies, enhancing efficacy while reducing systemic toxicity, representing promising advancements in targeted cancer therapy and drug delivery systems.

Immune Checkpoint Inhibitors (ICIs) [66]

Immune checkpoint inhibitors including pembrolizumab, nivolumab, and atezolizumab enhance immune responses by targeting PD-1, PD-L1, and CTLA-4, improving cancer cell destruction, especially when combined with other therapies.

Multitargeted Therapies [67]

Certain therapies exhibit multitargeted activity affecting multiple pathways. Crizotinib targets c-MET, ROS1, and ALK; nintedanib acts on FGFR, PDGFR, and VEGFR. Multitargeted approaches are valuable for addressing complex cancer cell signaling networks.

 

6.5 Immunotherapy Innovations

Immunotherapy has substantially transformed lung cancer treatment, particularly through immune checkpoint inhibitors and tailored approaches. These developments strengthen the immune system's capacity to target and eliminate cancer cells, resulting in improved patient outcomes.

6.5.1 Immune Checkpoint Inhibitors

 

Aspect

Details

Mechanism [68,69]

Anti-PD-1 and anti-PD-L1 antibodies block immunological checkpoints between T-cells and malignant cells, restoring anti-tumor immune responses.

Efficacy [69,70]

Clinical trial findings demonstrate survival improvements following checkpoint inhibitor administration in advanced NSCLC and SCLC cases.

Combination Therapies [71]

Combining checkpoint inhibitors with chemotherapy or radiation demonstrates synergistic effects, further enhancing treatment outcomes.

 

6.5.2 Personalized Immunotherapy Approaches

 

Strategy

Application

Biomarker-Driven Strategies [70,71]

Tailoring treatment based on genetic profiles and tumor characteristics enhances efficacy and minimizes adverse effects.

Adoptive Cell Therapies [71,72]

CAR T-cell therapy and therapeutic vaccines expedite specific immune responses focused on tumor antigens and potential tumor growths.

Future Directions [68,69]

Ongoing research aims to identify reliable biomarkers and develop technologies for personalized treatment, addressing challenges including resistance and immune-related side effects.
 

6.6 Emerging Therapies and Clinical Trials

Lung cancer treatment continues evolving through new therapies and clinical trials, creating additional strategies to improve patient outcomes. Promising areas of development include immunotherapies, targeted treatments, and combination approaches designed to address lung cancer complexities, especially in NSCLC.

6.6.1 Immunotherapy Advances

  • Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 have transformed NSCLC treatment by providing durable responses in patient subsets [73].
  • Novel immunotherapeutic agents under active investigation in ongoing clinical trials aim to enhance efficacy and overcome resistance [73].

6.6.2 Targeted Therapies

  • Targeted therapies have significantly improved survival rates, focusing on actionable mutations including EGFR, ALK, and KRAS [74].
  • Newer KRAS-directed therapies and pan-RAS inhibitors are being developed to address previously challenging mutations [74].

6.6.3 Combination Therapies

  • Combining immunotherapy with traditional treatments including chemotherapy and radiation is being investigated to enhance therapeutic efficacy and minimize resistance [60].
  • This multifaceted approach aims to personalize treatment and address lung cancer heterogeneity [60].

7. FUTURE DIRECTIONS AND INNOVATIONS

7.1 Potential Breakthroughs in Lung Cancer Research

The future of lung cancer research promises critical advancements, particularly through novel therapeutic approaches and precision medicine progress. Focus areas include gene-editing technologies, innovative immunotherapies, and improved diagnostic techniques, collectively targeting enhanced patient outcomes and treatment effectiveness.

7.1.1 CRISPR-Cas9 Gene Editing

  • CRISPR-Cas9 technology provides precise genomic editing, essential for targeted lung cancer treatments [75].
  • Efficient delivery vehicles, including viral vectors and lipid-based nanoparticles, are being developed to improve CRISPR application specificity and efficacy [75].
  • Current clinical trials investigate the feasibility and safety of these delivery methods, indicating promising futures for personalized medicine in lung cancer treatment [75].

7.1.2 CAR-NK Cell Therapy

  • Chimeric antigen receptor (CAR) natural killer (NK) cell therapy offers novel approaches with fewer side effect risks than conventional CAR T-cell therapies [76].
  • Early-stage clinical trials demonstrate extensive antitumor activity, indicating CAR-NK cells may become treatment staples in lung cancer [76].
  • This approach specifically targets and eliminates tumor cells while reducing immune-related toxicity possibilities [77].
  • Unlike CAR T-cell therapies, NK cells possess inherent abilities to identify and eliminate tumor cells without causing cytokine release syndrome (CRS) or graft-versus-host disease (GvHD) [77].
  • Preclinical studies using CAR-NK cells demonstrate significant antitumor activity, enhanced targeting, and persistence [77].

7.1.3 AI-Driven Diagnostics

  • Artificial intelligence-based diagnostic tools are increasingly utilized to enhance lung cancer detection effectiveness and accuracy [78].
  • Deep learning (DL) algorithms have been developed to detect lung nodules on computed tomography (CT) scans and chest radiographs [78].
  • These algorithms assist in selecting candidate nodules for malignancy prediction in indeterminate pulmonary nodules [78].
  • Convolutional neural networks (CNNs) demonstrate encouraging results in medical image analysis, facilitating lung cancer detection [79].
  • These models identify high-risk nodules, decreasing missed or incorrect diagnosis risks [79].

7.2 Role of AI and Big Data in Advancing Diagnostics and Treatment

Artificial intelligence (AI) and big data offer transformative potential for early identification, personalized therapy, and improved patient outcomes. Various AI technologies, including deep learning and machine learning, are applied to analyze high-volume genomics, imaging, and medical history data, achieving enhanced diagnostic accuracy and personalized treatment strategies.

7.2.1 AI in Diagnostics

Multimodal Frameworks: AI frameworks combining convolutional neural networks (CNNs) and artificial neural networks (ANNs) demonstrate notable accuracy in diagnosing lung cancer from imaging and clinical data, achieving up to 99% accuracy in some cases [80].

Deep Learning Techniques: Advanced deep learning methods enhance lung cancer detection efficiency in radiological imaging, focusing on improving algorithm performance and integrating these tools into clinical workflows [81].

7.2.2 Precision Medicine and Treatment

Personalized Therapies: AI is instrumental in precision medicine, enabling treatment plans tailored to individual genetic profiles and tumor characteristics, significantly improving therapeutic efficacy [70].

Immunotherapy Integration: AI combined with immunotherapy and targeted therapies represents potent strategies to improve patient outcomes and NSCLC survival rates [70].

7.2.3 Future Directions

Next-Generation Phenomics: AI integration with next-generation phenomics is expected to provide deeper insights into lung cancer biology, enabling novel biomarker and therapeutic target identification, thus fostering precision medicine advancements [82].

Ethical and Practical Challenges: Despite encouraging developments, issues including data quality, model interpretability, and ethical considerations require resolution to ensure successful clinical implementation [82].

7.3 Importance of Patient-Centric Care and Integrative Approaches

The future of lung cancer treatment emphasizes patient-centered and integrative approaches, with greater focus on quality of life (QoL) and individualized therapies. Recognition is growing that effective treatment must consider patients' subjective experiences and preferences alongside conventional clinical outcomes.

7.3.1 Patient-Centric Care Integration

Quality of Life Assessments: Recent studies indicate only 31.93% of Phase III lung cancer trials included QoL as an endpoint, highlighting significant gaps in understanding treatment impacts on patients' lives [83].

Educational Initiatives: Programs enhancing oncologists' skills in patient-centric approaches have demonstrated substantial improvements in knowledge and intent to provide equitable care, with 44-point increases in understanding team-based strategies [84].

7.3.2 Innovative Therapeutic Approaches

Precision Medicine and AI: AI incorporation in lung cancer management transforms treatment personalization, enabling improved diagnostic accuracy and tailored therapeutic strategies [85].

Combination Therapies: Emerging therapies, including immunotherapy and targeted agents, are combined to address lung cancer heterogeneity, potentially improving outcomes for advanced cases [60].

8. CHALLENGES IN LUNG CANCER MANAGEMENT

8.1 Drug Resistance Mechanisms

Acquired Resistance: Development of secondary mutations (e.g., EGFR T790M) limits targeted therapy efficacy, necessitating sequential treatment strategies.

Tumor Heterogeneity: Intratumoral genetic diversity contributes to treatment resistance and disease progression, challenging single-agent approaches.

Immune Resistance: Primary and acquired resistance to immunotherapy occurs through various mechanisms including loss of antigen presentation and immunosuppressive microenvironment development.

8.2 Access and Health Disparities

Geographic Disparities: Significant variations in advanced diagnostic and therapeutic technology access exist globally, with low- and middle-income countries facing substantial barriers.

Socioeconomic Factors: Financial toxicity, insurance coverage limitations, and healthcare infrastructure deficiencies impact treatment access and outcomes.

Rural-Urban Divide: Patients in rural areas often experience delayed diagnosis, limited access to specialized care, and increased travel burdens.

8.3 Late-Stage Diagnosis

Asymptomatic Early Disease: Early-stage lung cancer often presents asymptomatically, leading to advanced-stage diagnosis with poorer prognoses.

Screening Challenges: Low-dose CT screening implementation remains limited despite demonstrated mortality benefits, particularly in high-risk populations.

Awareness Gaps: Public and healthcare provider awareness of lung cancer symptoms and screening guidelines requires improvement.

8.4 Treatment-Related Toxicities

Immune-Related Adverse Events: Immunotherapy can trigger autoimmune complications affecting multiple organ systems, requiring careful monitoring and management.

Targeted Therapy Side Effects: Skin toxicity, diarrhea, and other specific adverse events impact patient quality of life and treatment adherence.

Cumulative Toxicities: Sequential and combination therapies may produce cumulative toxicities, complicating long-term management.

CONCLUSION

Lung cancer remains a leading cause of cancer-related mortality worldwide, presenting substantial challenges to global health systems. While tobacco smoking represents the primary etiological factor, air pollution, genetic predisposition, and occupational exposures contribute significantly to disease burden. Despite considerable medical advances, lung cancer frequently presents at advanced stages with limited therapeutic options, resulting in persistently poor outcomes. However, substantial progress provides grounds for optimism. Modern diagnostic tools including liquid biopsies and AI-enhanced imaging enable earlier detection with unprecedented precision. Treatment paradigms have evolved dramatically—targeted therapies and immunotherapies offer personalized options that reduce reliance on traditional chemotherapy's harsh side effects. These precision medicine approaches have transformed prognosis for patients with actionable mutations and favorable biomarker profiles. Nevertheless, significant obstacles persist. Drug resistance mechanisms, inequitable access to advanced treatments, and the physical and emotional toll on patients and families demand continued attention. The financial toxicity of novel therapies and healthcare disparities between high-income and low- and middle-income countries exacerbate these challenges.

Future lung cancer management will likely be transformed by emerging technologies. Artificial intelligence, big data analytics, and gene-editing technologies such as CRISPR hold potential to revolutionize diagnosis and treatment paradigms. CAR-NK cell therapies and novel immunotherapy combinations represent promising avenues for addressing treatment-resistant disease. However, technology alone is insufficient. A truly patient-centric approach—one prioritizing not merely survival but quality of life, psychological well-being, and patient preferences—is essential for optimal outcomes. The path forward requires sustained research investment, interdisciplinary collaboration, equitable healthcare access, and comprehensive support systems addressing the holistic needs of patients and their families. Through continued innovation and commitment to patient-centered care, we move toward a future where lung cancer transitions from a life-threatening diagnosis to a manageable chronic condition.

DECLARATIONS

Ethics Approval

This article does not include studies involving human participants or animals conducted by the authors. Therefore, ethics approval and consent to participate are not applicable.

Funding

This review was conducted without specific funding from public, commercial, or not-for-profit sectors.

Generative Artificial Intelligence (AI)

Generative AI tools were employed solely to assist in language refinement, summarization of existing literature, and structural organization of the manuscript. AI was not used to generate novel scientific content, interpret results, or draw conclusions. All information synthesized from AI outputs was cross-verified with primary literature sources, and the final content reflects the authors' independent analysis and critical judgment. The authors assume full responsibility for the accuracy, originality, and integrity of this work.

Consent for Publication

All authors have reviewed and approved the manuscript for submission and have given consent for its publication.

Competing Interests

The authors declare no competing interests.

Conflict of Interest

The authors declare no conflicts of interest. This ensures transparency and confirms that no financial or personal interests influenced this study.

Data Availability Statement

No new data were generated or analyzed in this study. Data sharing is not applicable.

Authors' Contributions

Uday R conceived the review idea and wrote the original manuscript. Manjunatha PM conceived the review idea and reviewed the manuscript. All other authors reviewed the manuscript.

Author declaration certificate

This is to certify that the reported work in the paper entitled " Piperine as a Bioavailability Enhancer: Molecular Mechanisms, Pharmacological Potential and Therapeutic Implications" submitted for publication is an original one and has not been submitted for publication elsewhere. I/we further certify that proper citations to the previously reported work have been given and no data/tables/figures have been quoted verbatim from other publications without giving due acknowledgement and without the permission of the author(s). The consent of all the authors of this paper has been obtained for submitting the paper to the Indian Journal of Natural Products and Resources.

REFERENCES

  1. Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, Zhang Z, Gao T, Zhang Y, Li L. Global burden and trends of lung cancer incidence and mortality. Chinese Medical Journal. 2023 Jul 5;136(13):1583-90.
  2. Cao W, Qin K, Li F, Chen W. Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN). Journal of the National Cancer Center. 2024 May 7.
  3. Jha AM, Kumar A, Abraham J, Firdaus H. Global Burden of Lung Cancer: Prognosis, Symptom Management, And Challenges with Pulmonary Fibrosis. International Journal of Trends in OncoScience. 2024 Jul 8:8-13.
  4. Zhang J, Li J, Xiong S, He Q, Bergin RJ, Emery JD, IJzerman MJ, Fitzmaurice C, Wang X, Li C, Zhu F. Global burden of lung cancer: implications from current evidence. Annals of Cancer Epidemiology. 2021 Mar 30;5.
  5. Cai L, Zhu CX, Zhang XL, Fang Y, Yang HY, Guo LW. Interpretation of global lung cancer statistics. Zhonghua Liu Xing Bing xue za zhi= Zhonghua Liuxingbingxue Zazhi. 2024 Apr 1;45(4):585-90.
  6. Agonsanou H, Figueiredo R, Bergeron M. Risk factors for the development of lung cancer around the world: a review. Exploration of Medicine. 2023 Dec 29;4(6):1168-88.
  7. Didkowska J, Wojciechowska U, Ma?czuk M, ?obaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Annals of translational medicine. 2016 Apr;4(8).
  8. Lakkimsetti M, Vanodia MP, Singh K, Goel S, Bathvar P, Patel DP, Vemparala P, Patel J, Amin V, Koyani HB, Gadhiya D. Evolving burden of lung cancer attributable to occupational carcinogens in 38 OECD countries: Global, national differences, age dynamics and implications for global health.
  9. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemporary Oncology/Wspó?czesna Onkologia. 2021 Feb 23;25(1):45-52.
  10. Islam M. What inherited genetic mechanisms underlie familial non-small cell lung cancer? 2024. https://doi.org/10.58445/rars.1205.
  11. Panagiotou E, Vathiotis I. Biological and therapeutic implications of the cancer-related germline mutation landscape in lung cancer. The Lancet Respiratory Medicine. 2024. https://doi.org/10.1016/s2213-2600(24)00124-3
  12. Lee JY, Bhandare RR, Boddu SHS, Shaik AB, Saktivel LP, Gupta G, Negi P, Barakat M, Singh SK, Dua K, Chellappan DK. Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer. Biomedicine & Pharmacotherapy. 2024;173:116275. https://doi.org/10.1016/j.biopha.2024.116275
  13. Fatima S, Kumar V, Kumar D. Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer. Medical Oncology. 2025 Feb 2;42(3):61.
  14. Ding W, Yang P, Zhao X, Wang X, Liu H, Su Q, Wang X, Li J, Gong Z, Zhang D, Wang X. Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations. Respiratory Research. 2024 Jan 18;25(1):40.
  15. Soca-Chafre G, Montiel-Dávalos A, De La Rosa-Velázquez IA, Caro-Sánchez CHS, Peña-Nieves A, Arrieta O. Multiple Molecular Targets Associated with Genomic Instability in Lung Cancer. Comparative and Functional Genomics. 2019;2019:9584504. https://doi.org/10.1155/2019/9584504
  16. Martinez VD, Sage AP, Marshall EA, Suzuki M, Goodarzi AA, Dellaire G, Lam WL. Oncogenetics of Lung Cancer Induced by Environmental Carcinogens. IntechOpen. 2018. https://doi.org/10.5772/INTECHOPEN.81064
  17. Shehata SA, Toraih EA, Ismail EA, Hagras AM, Elmorsy E, Fawzy MS. Vaping, Environmental Toxicants Exposure, and Lung Cancer Risk. Cancers. 2023. https://doi.org/10.3390/cancers15184525
  18. Liu Y, Xu Y, Li Y, Wei H. Identifying the Environmental Determinants of Lung Cancer: A Case Study of Henan, China. Geohealth. 2023;7. https://doi.org/10.1029/2023GH000794
  19. Clofent D, Culebras M, Loor K, Cruz MJ. Environmental pollution and lung cancer: the carcinogenic power of the air we breathe. Archivos de bronconeumologia. 2021 May;57(5):317-8.
  20. Samet JM. Environmental causes of lung cancer: what do we know in 2003? Chest. 2004 May 1;125(5):80S-3S.
  21. Hecht SS. Tobacco smoke carcinogens and lung cancer. Journal of the National Cancer Institute. 1999 Jul 21;91(14):1194-210.
  22. National Cancer Institute. Beta Carotene and Lung Cancer Risk. Cancer Trends Progress Report. 2022.
  23. Sharman R, Harris Z, Ernst B, Mussallem D, Larsen A, Gowin K. Lifestyle Factors and Cancer: A Narrative Review. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2024 Apr 1;8(2):166-83.
  24. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002 Dec;420(6917):860-7.
  25. Tan Z, Xue H, Sun Y, Zhang C, Song Y, Qi Y. The Role of Tumor Inflammatory Microenvironment in Lung Cancer. Frontiers in Pharmacology. 2021;12:688625. https://doi.org/10.3389/FPHAR.2021.688625
  26. Ai Y, Wang H, Zheng Q, Li S, Liu J, Huang J, Tang J, Meng X. Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19. Frontiers in Immunology. 2023 Mar 23;14:1174184.
  27. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. American Journal of Respiratory and Critical Care Medicine. 1998 May;157(5):1666-80.
  28. Shuaib M, Bansal T, Kumar S. Mycobacterium Tubercular Mediated Inflammation and Lung Carcinogenesis: Connecting Links. OBM Genetics. 2023;07(02):1-17. https://doi.org/10.21926/obm.genet.2302183
  29. Ma T, Tang Y, Wang T, Yang Y, Zhang Y, Wang R, Zhang Y, Li Y, Wu MC, Tang M, Hu X, Zou C, Ren Y, Liu H, Zhang Q, Li H, Wu M, Li J, Zhou X. Chronic pulmonary bacterial infection facilitates breast cancer lung metastasis by recruiting tumor-promoting MHCIIhi neutrophils. Signal Transduction and Targeted Therapy. 2023;8. https://doi.org/10.1038/s41392-023-01542-0
  30. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Review of Anticancer Therapy. 2008 Apr 1;8(4):605-15.
  31. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. The Lancet Global Health. 2016 Sep 1;4(9):e609-16.
  32. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, Xiong Y. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discovery. 2020 Jun 1;10(6):783-91.
  33. Di Bernardo A, Sahoo S, Balsamo M, Quaranta E, Jolly MK, Bertolini G, Roz L. Abstract 7376: Modeling the dynamics of lung cancer cells along the epithelial-mesenchymal spectrum in the stem and non-stem cell compartments. Cancer Research. 2024. https://doi.org/10.1158/1538-7445.am2024-7376
  34. Zhou Y, Chai S, Chen Y, Guo P. Analysis of gene mutation spectrum and prevention and treatment of lung cancer patients in Qujing, Yunnan Province, China. 2023. https://doi.org/10.21203/rs.3.rs-3503267/v1
  35. Yang Z, Zheng L, Wu Y, Luo N, Zhang Q, Bu X, Sun T, Qi C. Lung cancer patients with germline mutations have a unique fusion molecular spectrum. Journal of Clinical Oncology. 2022;40(16_suppl):e21009. https://doi.org/10.1200/jco.2022.40.16_suppl.e21009
  36. Zheng J, Fu FX, Shen DL, Qing W, Bo X. Progress in the Application of Energy-spectrum CT Imaging and Radiomics for the Diagnosis of Lung Cancer and Subtype Differentiation. Advances in Engineering Technology Research. 2023;1(3):596. https://doi.org/10.56028/aetr.3.1.596
  37. Slomka PJ, Pan T, Germano G. Recent advances and future progress in PET instrumentation. Seminars in Nuclear Medicine. 2016 Jan 1;46(1):5-19. WB Saunders.
  38. Hussain D, Abbas N, Khan J. Recent Breakthroughs in PET-CT Multimodality Imaging: Innovations and Clinical Impact. Bioengineering. 2024 Nov 30;11(12):1213.
  39. Townsend DW. Physical principles and technology of clinical PET imaging. Annals-Academy of Medicine Singapore. 2004 Mar 1;33(2):133-45.
  40. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R. A combined PET/CT scanner for clinical oncology. Journal of Nuclear Medicine. 2000 Aug 1;41(8):1369-79.
  41. Kerna NA, Ngwu DC, Kadivi K, Carsrud NDV, Pruitt KD, Flores JV, Holets HM, Jomsky BM, Chawla S, Azi CI, McKee D, Nwokorie U, Anderson J, Dugeri JL, Hammam HSH, Chiedozie OB, Nnake I, David CO, Adadzi J. Transformative Advancements in Diagnostic Imaging: Reducing Risks, Enhancing Accuracy, and Promoting Sustainability. European Journal of Medical and Health Research. 2024;2(5):153-172. https://doi.org/10.59324/ejmhr.2024.2(5).16
  42. More A, Kaur S, Bhatele S, Vasdev N, Gupta T, Pawar B, Tekade RK. Biomarkers: Revolutionizing disease monitoring and therapeutic strategies. 2024:1-25. Elsevier BV. https://doi.org/10.1016/b978-0-443-15842-1.00002-8
  43. Kibwe HM. Advances in molecular diagnostics for cardiovascular diseases: Techniques and applications. International Medical Science Research Journal. 2023;3(3):166-182. https://doi.org/10.51594/imsrj.v3i3.1630
  44. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer. 2017 Apr;17(4):223-38.
  45. Ganguly K. Biomarker-the molecular detective. 2024:214-224. https://doi.org/10.58532/v3bbbt14p2ch7
  46. Chornet CR. Molecular diagnosis of gene mutation and inherited diseases. 2023:425-455. Elsevier eBooks. https://doi.org/10.1016/b978-0-323-91788-9.00013-2
  47. Rutkowska-Kawalec W, Michalczuk K, Fabian D, Kurowski M, Leszczy?ska-Knaga E, Jakubczyk N, Moczyd?owski P, Ryglewicz M, Gliwa A, Kuczapska K. Liquid biopsy - a review. Journal of Education, Health and Sport. 2025;77:56584. https://doi.org/10.12775/jehs.2025.77.56584
  48. Pandey S, Yadav PK. Liquid Biopsy in Cancer Management: Integrating Diagnostics and Clinical Applications. Practical Laboratory Medicine. 2024:e00446. https://doi.org/10.1016/j.plabm.2024.e00446
  49. Kalligosfyri PM, Lamprou E, Kalogianni DP. Emerging Sensing Technologies for Liquid Biopsy Applications: Steps Closer to Personalized Medicine. Sensors. 2024;24(24):7902. https://doi.org/10.3390/s24247902
  50. Yazdi Z, Roshannezhad S, Sharif S, Abbaszadegan MR. Recent progress in prompt molecular detection of liquid biopsy using Cas enzymes: innovative approaches for cancer diagnosis and analysis. Journal of Translational Medicine. 2024;22(1). https://doi.org/10.1186/s12967-024-05908-y
  51. Khan Ibrar JA, Albalkhi I, Garatli S, Migliore M. Recent Advancements in Minimally Invasive Surgery for Early-Stage Non-Small Cell Lung Cancer: A Narrative Review. 2024. https://doi.org/10.20944/preprints202405.0332.v1
  52. D'Amours MF, Wu FTH, Theisen-Lauk O, Chan E, McGuire AL, Ho C. Surgically Resectable Non-Small Cell Lung Cancer: A Contemporary Approach. European Respiratory Journal. 2024:2400332. https://doi.org/10.1183/13993003.00332-2024
  53. Huang J. Advancements in NSCLC Treatment: Efficacy and Mechanisms of Surgery, Targeted Therapy, and Immunotherapy. Transactions on Materials, Biotechnology and Life Sciences. 2024;7:27-32. https://doi.org/10.62051/wyn27m95
  54. Shirai K, Aoki S, Endo M, Takahashi Y, Fukuda Y, Akahane K, Musha A, Sato H, Wakatsuki M, Ishikawa H, Sasaki R. Recent developments in the field of radiotherapy for the management of lung cancer. Japanese Journal of Radiology. 2024. https://doi.org/10.1007/s11604-024-01663-8
  55. Lee KN, Owen D. Advances in Stereotactic Body Radiation Therapy for Lung Cancer. The Cancer Journal. 2024;30(6):401-406. https://doi.org/10.1097/ppo.0000000000000753
  56. Amorim MS, Costa P, Costa MA. The Radiotherapy: Basic Concepts And Recent Techniques Advances For Thoracic Malignancies. Portuguese Journal of Cardiac Thoracic and Vascular Surgery. 2023;30(2):35-43. https://doi.org/10.48729/pjctvs.355
  57. Chicas-Sett R, Zafra-Martin J, Morales-Orue I, Castilla-Martinez J, Berenguer-Frances MA, González-Rodríguez E, Rodriguez-Abreu D, Couñago F. Immunoradiotherapy as An Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent. Cancers. 2020;12(8):2178. https://doi.org/10.3390/CANCERS12082178
  58. Lazaros G. Chemotherapeutic Protocols for the Treatment of Lung Cancer. Springer eBooks. 2022:291-305. https://doi.org/10.1007/978-3-031-10839-6_9
  59. Lee SH. Chemotherapy for Lung Cancer in the Era of Personalized Medicine. Tuberculosis and Respiratory Diseases. 2019;82(3):179-189. https://doi.org/10.4046/TRD.2018.0068
  60. La'ah A, Chiou SH. Cutting-Edge Therapies for Lung Cancer. Cells. 2024;13. https://doi.org/10.3390/cells13050436
  61. Winiarczyk K, Piórek A, Krzakowski M. ALK, ROS1 and EGFR next-generation tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Oncology in Clinical Practice. 2019;15(3):150-7.
  62. Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non?small cell lung cancer—recent advances and future perspectives. International Journal of Cancer. 2016 Jun 1;138(11):2549-61.
  63. Malik SM, Pazdur R, Abrams JS, Socinski MA, Sause WT, Harpole Jr DH, Welch JJ, Korn EL, Ullmann CD, Hirsch FR. Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. Journal of Thoracic Oncology. 2014 Oct 1;9(10):1443-8.
  64. Neijssen J, Cardoso RM, Chevalier KM, Wiegman L, Valerius T, Anderson GM, Moores SL, Schuurman J, Parren PW, Strohl WR, Chiu ML. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. Journal of Biological Chemistry. 2021 Jan 1;296.
  65. Reyes, Amanda, Pharaon, Rebecca R, Mohanty, Atish, and Massarelli, E.. 2023. "Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?". Cancers. https://doi.org/10.3390/cancers15123162
  66. Cali, Byron Cristobal Llongo, Jaramillo, Jorge Eduardo Paredes, Navas, Jennifer Alicia Lvarez, Quemag, Carlos Alan Buesaquillo, Serrano, Natalia Quintero, Zambrano, Wagnner Ariol Intriago, and Vasquez, Elias David Suarez. 2024. "Comparative efficacy of targeted therapies and immunotherapy in advanced non-small cell lung cancer: a systematic review". International Journal of Research in Medical Sciences. https://doi.org/10.18203/2320-6012.ijrms20242275
  67. Yumura, Masako, Nagano, Tatsuya, and Nishimura, Yoshihiro. 2020. "Novel Multitarget Therapies for Lung Cancer and Respiratory Disease". Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/molecules25173987
  68. Li, C., Yuan, X., & Yi, P. (2025). The Role of Immunotherapy in Lung Cancer Treatment: Current Strategies, Future Directions, and Insights into Metastasis and Immune Microenvironment. Current Gene Therapy, 25. https://doi.org/10.2174/0115665232340926241105064739
  69. Santos, E. A. de A., Silva, A. L. G., Cachoeira, J. V. M., & Filho, R. I. M. G. (2024). Imunoterapia no câncer de pulmão: eficácia e perspectivas do usode inibidores de checkpoint imunológico. RCMOS. https://doi.org/10.51473/rcmos.v1i2.2024.649
  70. Kedar, P., Bhattacharya, S., Kanugo, A., & Prajapati, B. G. (2025). Novel Strategies for the Treatment of Lung Cancer: An In-depth Analysis of the Use of Immunotherapy, Precision Medicine, and Artificial Intelligence to Improve Prognoses. Current Medicinal Chemistry, 32. https://doi.org/10.2174/0109298673347323241119184648
  71. Garg, P. K., Pareek, S., Kulkarni, P., Horné, D., Salgia, R., & Singhal, S. S. (2024). Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment. Stomatology, 13(21), 6537. https://doi.org/10.3390/jcm13216537
  72. Ghemrawi, R., Abuamer, L., Kremesh, S., Hussien, G., Ahmed, R., Mousa, W. K., Khoder, G., & Khair, M. (2024). Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Advances in Cardiovascular Diseases, 12(9), 2158. https://doi.org/10.3390/biomedicines12092158
  73. Wolf, E. B., Camargo Correia, G. S. de, Li, S., Zhao, Y., Manochakian, R., & Lou, Y. (2025). Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer. Vaccines, 13(2), 128. https://doi.org/10.3390/vaccines13020128
  74. Mina, S. A., Shanshal, M., Leventakos, K., & Parikh, K. (2025). Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC). Cancers, 17(3), 353. https://doi.org/10.3390/cancers17030353
  75. Singh, D. (2024). Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies. Aaps Pharmscitech, 25(5). https://doi.org/10.1208/s12249-024-02834-6
  76. Liu, F., Miao, X., Han, L., & Xiao, S. (2024). Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future? Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1390006
  77. Liu F, Miao X, Han L, Song X. Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?. Frontiers in Oncology. 2024 May 28;14:1390006.
  78. Lee JH, Hwang EJ, Kim H, Park CM. A narrative review of deep learning applications in lung cancer research: from screening to prognostication. Translational Lung Cancer Research. 2022 Jun;11(6):1217.
  79. Khattar S, Aftaab M, Verma T, Patial D, Kaur B, San HT, Kaur B. Deep learning-based lung cancer detection using convolutional neural networks. InAIP Conference Proceedings 2024 Mar 19 (Vol. 3072, No. 1). AIP Publishing.
  80. Oncu, E. (2024). Multimodal AI Framework for Lung Cancer Diagnosis: Integrating CNN and ANN Models for Imaging and Clinical Data Analysis. https://doi.org/10.20944/preprints202412.0033.v1
  81. Jozi, N. S., & Al–Suhail, G. A. (2024). Lung Cancer Detection in Radiological Imaging using Deep Learning: A Review. 1–8. https://doi.org/10.1109/ciees62939.2024.10811230
  82. Dasgupta, S. (2024). Next-Generation Cancer Phenomics: A Transformative Approach to Unraveling Lung Cancer Complexity and Advancing Precision Medicine. Omics A Journal of Integrative Biology. https://doi.org/10.1089/omi.2024.0175
  83. Kalantri, S., Sainatham, C., Tallapalli, J. R., Singh, R., & Kloecker, G. (2024). Patient-centered perspectives: Examining quality-of-life integration in phase III lung cancer trials (2019-2023). Journal of Clinical Oncology, 42(16_suppl), e23181. https://doi.org/10.1200/jco.2024.42.16_suppl.e23181
  84. Wilfong, K., Beyer, M., Basu Roy, U. K., Martin, N. A., Liu, S. V., Wills, D. M., & Drew, H. (2024). Enhancing oncologist knowledge and skills through patient-centric medical education: A collaborative approach with LUNGevity. Journal of Clinical Oncology, 42(16_suppl), e21007. https://doi.org/10.1200/jco.2024.42.16_suppl.e21007
  85. Lococo, F., Ghaly, G., Flamini, S., Campanella, A., Chiappetta, M., Bria, E., Vita, E., Tortora, G., Evangelista, J., Sassorossi, C., Congedo, M. T., Valentini, V., Sala, E., Cesario, A., Margaritora, S., Boldrini, L., & Mohammed, A. (2024). Artificial intelligence applications in personalizing lung cancer management: state of the art and future perspectives. Journal of Thoracic Disease, 16(10), 7096–7110. https://doi.org/10.21037/jtd-24-244

Reference

  1. Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, Zhang Z, Gao T, Zhang Y, Li L. Global burden and trends of lung cancer incidence and mortality. Chinese Medical Journal. 2023 Jul 5;136(13):1583-90.
  2. Cao W, Qin K, Li F, Chen W. Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN). Journal of the National Cancer Center. 2024 May 7.
  3. Jha AM, Kumar A, Abraham J, Firdaus H. Global Burden of Lung Cancer: Prognosis, Symptom Management, And Challenges with Pulmonary Fibrosis. International Journal of Trends in OncoScience. 2024 Jul 8:8-13.
  4. Zhang J, Li J, Xiong S, He Q, Bergin RJ, Emery JD, IJzerman MJ, Fitzmaurice C, Wang X, Li C, Zhu F. Global burden of lung cancer: implications from current evidence. Annals of Cancer Epidemiology. 2021 Mar 30;5.
  5. Cai L, Zhu CX, Zhang XL, Fang Y, Yang HY, Guo LW. Interpretation of global lung cancer statistics. Zhonghua Liu Xing Bing xue za zhi= Zhonghua Liuxingbingxue Zazhi. 2024 Apr 1;45(4):585-90.
  6. Agonsanou H, Figueiredo R, Bergeron M. Risk factors for the development of lung cancer around the world: a review. Exploration of Medicine. 2023 Dec 29;4(6):1168-88.
  7. Didkowska J, Wojciechowska U, Ma?czuk M, ?obaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Annals of translational medicine. 2016 Apr;4(8).
  8. Lakkimsetti M, Vanodia MP, Singh K, Goel S, Bathvar P, Patel DP, Vemparala P, Patel J, Amin V, Koyani HB, Gadhiya D. Evolving burden of lung cancer attributable to occupational carcinogens in 38 OECD countries: Global, national differences, age dynamics and implications for global health.
  9. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemporary Oncology/Wspó?czesna Onkologia. 2021 Feb 23;25(1):45-52.
  10. Islam M. What inherited genetic mechanisms underlie familial non-small cell lung cancer? 2024. https://doi.org/10.58445/rars.1205.
  11. Panagiotou E, Vathiotis I. Biological and therapeutic implications of the cancer-related germline mutation landscape in lung cancer. The Lancet Respiratory Medicine. 2024. https://doi.org/10.1016/s2213-2600(24)00124-3
  12. Lee JY, Bhandare RR, Boddu SHS, Shaik AB, Saktivel LP, Gupta G, Negi P, Barakat M, Singh SK, Dua K, Chellappan DK. Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer. Biomedicine & Pharmacotherapy. 2024;173:116275. https://doi.org/10.1016/j.biopha.2024.116275
  13. Fatima S, Kumar V, Kumar D. Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer. Medical Oncology. 2025 Feb 2;42(3):61.
  14. Ding W, Yang P, Zhao X, Wang X, Liu H, Su Q, Wang X, Li J, Gong Z, Zhang D, Wang X. Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations. Respiratory Research. 2024 Jan 18;25(1):40.
  15. Soca-Chafre G, Montiel-Dávalos A, De La Rosa-Velázquez IA, Caro-Sánchez CHS, Peña-Nieves A, Arrieta O. Multiple Molecular Targets Associated with Genomic Instability in Lung Cancer. Comparative and Functional Genomics. 2019;2019:9584504. https://doi.org/10.1155/2019/9584504
  16. Martinez VD, Sage AP, Marshall EA, Suzuki M, Goodarzi AA, Dellaire G, Lam WL. Oncogenetics of Lung Cancer Induced by Environmental Carcinogens. IntechOpen. 2018. https://doi.org/10.5772/INTECHOPEN.81064
  17. Shehata SA, Toraih EA, Ismail EA, Hagras AM, Elmorsy E, Fawzy MS. Vaping, Environmental Toxicants Exposure, and Lung Cancer Risk. Cancers. 2023. https://doi.org/10.3390/cancers15184525
  18. Liu Y, Xu Y, Li Y, Wei H. Identifying the Environmental Determinants of Lung Cancer: A Case Study of Henan, China. Geohealth. 2023;7. https://doi.org/10.1029/2023GH000794
  19. Clofent D, Culebras M, Loor K, Cruz MJ. Environmental pollution and lung cancer: the carcinogenic power of the air we breathe. Archivos de bronconeumologia. 2021 May;57(5):317-8.
  20. Samet JM. Environmental causes of lung cancer: what do we know in 2003? Chest. 2004 May 1;125(5):80S-3S.
  21. Hecht SS. Tobacco smoke carcinogens and lung cancer. Journal of the National Cancer Institute. 1999 Jul 21;91(14):1194-210.
  22. National Cancer Institute. Beta Carotene and Lung Cancer Risk. Cancer Trends Progress Report. 2022.
  23. Sharman R, Harris Z, Ernst B, Mussallem D, Larsen A, Gowin K. Lifestyle Factors and Cancer: A Narrative Review. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2024 Apr 1;8(2):166-83.
  24. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002 Dec;420(6917):860-7.
  25. Tan Z, Xue H, Sun Y, Zhang C, Song Y, Qi Y. The Role of Tumor Inflammatory Microenvironment in Lung Cancer. Frontiers in Pharmacology. 2021;12:688625. https://doi.org/10.3389/FPHAR.2021.688625
  26. Ai Y, Wang H, Zheng Q, Li S, Liu J, Huang J, Tang J, Meng X. Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19. Frontiers in Immunology. 2023 Mar 23;14:1174184.
  27. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. American Journal of Respiratory and Critical Care Medicine. 1998 May;157(5):1666-80.
  28. Shuaib M, Bansal T, Kumar S. Mycobacterium Tubercular Mediated Inflammation and Lung Carcinogenesis: Connecting Links. OBM Genetics. 2023;07(02):1-17. https://doi.org/10.21926/obm.genet.2302183
  29. Ma T, Tang Y, Wang T, Yang Y, Zhang Y, Wang R, Zhang Y, Li Y, Wu MC, Tang M, Hu X, Zou C, Ren Y, Liu H, Zhang Q, Li H, Wu M, Li J, Zhou X. Chronic pulmonary bacterial infection facilitates breast cancer lung metastasis by recruiting tumor-promoting MHCIIhi neutrophils. Signal Transduction and Targeted Therapy. 2023;8. https://doi.org/10.1038/s41392-023-01542-0
  30. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Review of Anticancer Therapy. 2008 Apr 1;8(4):605-15.
  31. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. The Lancet Global Health. 2016 Sep 1;4(9):e609-16.
  32. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, Xiong Y. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discovery. 2020 Jun 1;10(6):783-91.
  33. Di Bernardo A, Sahoo S, Balsamo M, Quaranta E, Jolly MK, Bertolini G, Roz L. Abstract 7376: Modeling the dynamics of lung cancer cells along the epithelial-mesenchymal spectrum in the stem and non-stem cell compartments. Cancer Research. 2024. https://doi.org/10.1158/1538-7445.am2024-7376
  34. Zhou Y, Chai S, Chen Y, Guo P. Analysis of gene mutation spectrum and prevention and treatment of lung cancer patients in Qujing, Yunnan Province, China. 2023. https://doi.org/10.21203/rs.3.rs-3503267/v1
  35. Yang Z, Zheng L, Wu Y, Luo N, Zhang Q, Bu X, Sun T, Qi C. Lung cancer patients with germline mutations have a unique fusion molecular spectrum. Journal of Clinical Oncology. 2022;40(16_suppl):e21009. https://doi.org/10.1200/jco.2022.40.16_suppl.e21009
  36. Zheng J, Fu FX, Shen DL, Qing W, Bo X. Progress in the Application of Energy-spectrum CT Imaging and Radiomics for the Diagnosis of Lung Cancer and Subtype Differentiation. Advances in Engineering Technology Research. 2023;1(3):596. https://doi.org/10.56028/aetr.3.1.596
  37. Slomka PJ, Pan T, Germano G. Recent advances and future progress in PET instrumentation. Seminars in Nuclear Medicine. 2016 Jan 1;46(1):5-19. WB Saunders.
  38. Hussain D, Abbas N, Khan J. Recent Breakthroughs in PET-CT Multimodality Imaging: Innovations and Clinical Impact. Bioengineering. 2024 Nov 30;11(12):1213.
  39. Townsend DW. Physical principles and technology of clinical PET imaging. Annals-Academy of Medicine Singapore. 2004 Mar 1;33(2):133-45.
  40. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R. A combined PET/CT scanner for clinical oncology. Journal of Nuclear Medicine. 2000 Aug 1;41(8):1369-79.
  41. Kerna NA, Ngwu DC, Kadivi K, Carsrud NDV, Pruitt KD, Flores JV, Holets HM, Jomsky BM, Chawla S, Azi CI, McKee D, Nwokorie U, Anderson J, Dugeri JL, Hammam HSH, Chiedozie OB, Nnake I, David CO, Adadzi J. Transformative Advancements in Diagnostic Imaging: Reducing Risks, Enhancing Accuracy, and Promoting Sustainability. European Journal of Medical and Health Research. 2024;2(5):153-172. https://doi.org/10.59324/ejmhr.2024.2(5).16
  42. More A, Kaur S, Bhatele S, Vasdev N, Gupta T, Pawar B, Tekade RK. Biomarkers: Revolutionizing disease monitoring and therapeutic strategies. 2024:1-25. Elsevier BV. https://doi.org/10.1016/b978-0-443-15842-1.00002-8
  43. Kibwe HM. Advances in molecular diagnostics for cardiovascular diseases: Techniques and applications. International Medical Science Research Journal. 2023;3(3):166-182. https://doi.org/10.51594/imsrj.v3i3.1630
  44. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer. 2017 Apr;17(4):223-38.
  45. Ganguly K. Biomarker-the molecular detective. 2024:214-224. https://doi.org/10.58532/v3bbbt14p2ch7
  46. Chornet CR. Molecular diagnosis of gene mutation and inherited diseases. 2023:425-455. Elsevier eBooks. https://doi.org/10.1016/b978-0-323-91788-9.00013-2
  47. Rutkowska-Kawalec W, Michalczuk K, Fabian D, Kurowski M, Leszczy?ska-Knaga E, Jakubczyk N, Moczyd?owski P, Ryglewicz M, Gliwa A, Kuczapska K. Liquid biopsy - a review. Journal of Education, Health and Sport. 2025;77:56584. https://doi.org/10.12775/jehs.2025.77.56584
  48. Pandey S, Yadav PK. Liquid Biopsy in Cancer Management: Integrating Diagnostics and Clinical Applications. Practical Laboratory Medicine. 2024:e00446. https://doi.org/10.1016/j.plabm.2024.e00446
  49. Kalligosfyri PM, Lamprou E, Kalogianni DP. Emerging Sensing Technologies for Liquid Biopsy Applications: Steps Closer to Personalized Medicine. Sensors. 2024;24(24):7902. https://doi.org/10.3390/s24247902
  50. Yazdi Z, Roshannezhad S, Sharif S, Abbaszadegan MR. Recent progress in prompt molecular detection of liquid biopsy using Cas enzymes: innovative approaches for cancer diagnosis and analysis. Journal of Translational Medicine. 2024;22(1). https://doi.org/10.1186/s12967-024-05908-y
  51. Khan Ibrar JA, Albalkhi I, Garatli S, Migliore M. Recent Advancements in Minimally Invasive Surgery for Early-Stage Non-Small Cell Lung Cancer: A Narrative Review. 2024. https://doi.org/10.20944/preprints202405.0332.v1
  52. D'Amours MF, Wu FTH, Theisen-Lauk O, Chan E, McGuire AL, Ho C. Surgically Resectable Non-Small Cell Lung Cancer: A Contemporary Approach. European Respiratory Journal. 2024:2400332. https://doi.org/10.1183/13993003.00332-2024
  53. Huang J. Advancements in NSCLC Treatment: Efficacy and Mechanisms of Surgery, Targeted Therapy, and Immunotherapy. Transactions on Materials, Biotechnology and Life Sciences. 2024;7:27-32. https://doi.org/10.62051/wyn27m95
  54. Shirai K, Aoki S, Endo M, Takahashi Y, Fukuda Y, Akahane K, Musha A, Sato H, Wakatsuki M, Ishikawa H, Sasaki R. Recent developments in the field of radiotherapy for the management of lung cancer. Japanese Journal of Radiology. 2024. https://doi.org/10.1007/s11604-024-01663-8
  55. Lee KN, Owen D. Advances in Stereotactic Body Radiation Therapy for Lung Cancer. The Cancer Journal. 2024;30(6):401-406. https://doi.org/10.1097/ppo.0000000000000753
  56. Amorim MS, Costa P, Costa MA. The Radiotherapy: Basic Concepts And Recent Techniques Advances For Thoracic Malignancies. Portuguese Journal of Cardiac Thoracic and Vascular Surgery. 2023;30(2):35-43. https://doi.org/10.48729/pjctvs.355
  57. Chicas-Sett R, Zafra-Martin J, Morales-Orue I, Castilla-Martinez J, Berenguer-Frances MA, González-Rodríguez E, Rodriguez-Abreu D, Couñago F. Immunoradiotherapy as An Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent. Cancers. 2020;12(8):2178. https://doi.org/10.3390/CANCERS12082178
  58. Lazaros G. Chemotherapeutic Protocols for the Treatment of Lung Cancer. Springer eBooks. 2022:291-305. https://doi.org/10.1007/978-3-031-10839-6_9
  59. Lee SH. Chemotherapy for Lung Cancer in the Era of Personalized Medicine. Tuberculosis and Respiratory Diseases. 2019;82(3):179-189. https://doi.org/10.4046/TRD.2018.0068
  60. La'ah A, Chiou SH. Cutting-Edge Therapies for Lung Cancer. Cells. 2024;13. https://doi.org/10.3390/cells13050436
  61. Winiarczyk K, Piórek A, Krzakowski M. ALK, ROS1 and EGFR next-generation tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Oncology in Clinical Practice. 2019;15(3):150-7.
  62. Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non?small cell lung cancer—recent advances and future perspectives. International Journal of Cancer. 2016 Jun 1;138(11):2549-61.
  63. Malik SM, Pazdur R, Abrams JS, Socinski MA, Sause WT, Harpole Jr DH, Welch JJ, Korn EL, Ullmann CD, Hirsch FR. Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. Journal of Thoracic Oncology. 2014 Oct 1;9(10):1443-8.
  64. Neijssen J, Cardoso RM, Chevalier KM, Wiegman L, Valerius T, Anderson GM, Moores SL, Schuurman J, Parren PW, Strohl WR, Chiu ML. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. Journal of Biological Chemistry. 2021 Jan 1;296.
  65. Reyes, Amanda, Pharaon, Rebecca R, Mohanty, Atish, and Massarelli, E.. 2023. "Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?". Cancers. https://doi.org/10.3390/cancers15123162
  66. Cali, Byron Cristobal Llongo, Jaramillo, Jorge Eduardo Paredes, Navas, Jennifer Alicia Lvarez, Quemag, Carlos Alan Buesaquillo, Serrano, Natalia Quintero, Zambrano, Wagnner Ariol Intriago, and Vasquez, Elias David Suarez. 2024. "Comparative efficacy of targeted therapies and immunotherapy in advanced non-small cell lung cancer: a systematic review". International Journal of Research in Medical Sciences. https://doi.org/10.18203/2320-6012.ijrms20242275
  67. Yumura, Masako, Nagano, Tatsuya, and Nishimura, Yoshihiro. 2020. "Novel Multitarget Therapies for Lung Cancer and Respiratory Disease". Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/molecules25173987
  68. Li, C., Yuan, X., & Yi, P. (2025). The Role of Immunotherapy in Lung Cancer Treatment: Current Strategies, Future Directions, and Insights into Metastasis and Immune Microenvironment. Current Gene Therapy, 25. https://doi.org/10.2174/0115665232340926241105064739
  69. Santos, E. A. de A., Silva, A. L. G., Cachoeira, J. V. M., & Filho, R. I. M. G. (2024). Imunoterapia no câncer de pulmão: eficácia e perspectivas do usode inibidores de checkpoint imunológico. RCMOS. https://doi.org/10.51473/rcmos.v1i2.2024.649
  70. Kedar, P., Bhattacharya, S., Kanugo, A., & Prajapati, B. G. (2025). Novel Strategies for the Treatment of Lung Cancer: An In-depth Analysis of the Use of Immunotherapy, Precision Medicine, and Artificial Intelligence to Improve Prognoses. Current Medicinal Chemistry, 32. https://doi.org/10.2174/0109298673347323241119184648
  71. Garg, P. K., Pareek, S., Kulkarni, P., Horné, D., Salgia, R., & Singhal, S. S. (2024). Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment. Stomatology, 13(21), 6537. https://doi.org/10.3390/jcm13216537
  72. Ghemrawi, R., Abuamer, L., Kremesh, S., Hussien, G., Ahmed, R., Mousa, W. K., Khoder, G., & Khair, M. (2024). Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Advances in Cardiovascular Diseases, 12(9), 2158. https://doi.org/10.3390/biomedicines12092158
  73. Wolf, E. B., Camargo Correia, G. S. de, Li, S., Zhao, Y., Manochakian, R., & Lou, Y. (2025). Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer. Vaccines, 13(2), 128. https://doi.org/10.3390/vaccines13020128
  74. Mina, S. A., Shanshal, M., Leventakos, K., & Parikh, K. (2025). Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC). Cancers, 17(3), 353. https://doi.org/10.3390/cancers17030353
  75. Singh, D. (2024). Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies. Aaps Pharmscitech, 25(5). https://doi.org/10.1208/s12249-024-02834-6
  76. Liu, F., Miao, X., Han, L., & Xiao, S. (2024). Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future? Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1390006
  77. Liu F, Miao X, Han L, Song X. Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?. Frontiers in Oncology. 2024 May 28;14:1390006.
  78. Lee JH, Hwang EJ, Kim H, Park CM. A narrative review of deep learning applications in lung cancer research: from screening to prognostication. Translational Lung Cancer Research. 2022 Jun;11(6):1217.
  79. Khattar S, Aftaab M, Verma T, Patial D, Kaur B, San HT, Kaur B. Deep learning-based lung cancer detection using convolutional neural networks. InAIP Conference Proceedings 2024 Mar 19 (Vol. 3072, No. 1). AIP Publishing.
  80. Oncu, E. (2024). Multimodal AI Framework for Lung Cancer Diagnosis: Integrating CNN and ANN Models for Imaging and Clinical Data Analysis. https://doi.org/10.20944/preprints202412.0033.v1
  81. Jozi, N. S., & Al–Suhail, G. A. (2024). Lung Cancer Detection in Radiological Imaging using Deep Learning: A Review. 1–8. https://doi.org/10.1109/ciees62939.2024.10811230
  82. Dasgupta, S. (2024). Next-Generation Cancer Phenomics: A Transformative Approach to Unraveling Lung Cancer Complexity and Advancing Precision Medicine. Omics A Journal of Integrative Biology. https://doi.org/10.1089/omi.2024.0175
  83. Kalantri, S., Sainatham, C., Tallapalli, J. R., Singh, R., & Kloecker, G. (2024). Patient-centered perspectives: Examining quality-of-life integration in phase III lung cancer trials (2019-2023). Journal of Clinical Oncology, 42(16_suppl), e23181. https://doi.org/10.1200/jco.2024.42.16_suppl.e23181
  84. Wilfong, K., Beyer, M., Basu Roy, U. K., Martin, N. A., Liu, S. V., Wills, D. M., & Drew, H. (2024). Enhancing oncologist knowledge and skills through patient-centric medical education: A collaborative approach with LUNGevity. Journal of Clinical Oncology, 42(16_suppl), e21007. https://doi.org/10.1200/jco.2024.42.16_suppl.e21007
  85. Lococo, F., Ghaly, G., Flamini, S., Campanella, A., Chiappetta, M., Bria, E., Vita, E., Tortora, G., Evangelista, J., Sassorossi, C., Congedo, M. T., Valentini, V., Sala, E., Cesario, A., Margaritora, S., Boldrini, L., & Mohammed, A. (2024). Artificial intelligence applications in personalizing lung cancer management: state of the art and future perspectives. Journal of Thoracic Disease, 16(10), 7096–7110. https://doi.org/10.21037/jtd-24-244

Photo
Uday R.
Corresponding author

Acharya & BM Reddy College of Pharmacy, Acharya Dr. Sarvepalli Radhakrishna Road, Achit Nagar (Post), Soldevanahalli, Bengaluru-560107, India

Photo
Dr. Manjunatha P. M.
Co-author

Acharya & BM Reddy College of Pharmacy, Acharya Dr. Sarvepalli Radhakrishna Road, Achit Nagar (Post), Soldevanahalli, Bengaluru-560107, India

Photo
Nageena Taj
Co-author

Acharya & BM Reddy College of Pharmacy, Acharya Dr. Sarvepalli Radhakrishna Road, Achit Nagar (Post), Soldevanahalli, Bengaluru-560107, India

Photo
Nikhil H. R.
Co-author

Acharya & BM Reddy College of Pharmacy, Acharya Dr. Sarvepalli Radhakrishna Road, Achit Nagar (Post), Soldevanahalli, Bengaluru-560107, India

Photo
Rajesh A.
Co-author

Acharya & BM Reddy College of Pharmacy, Acharya Dr. Sarvepalli Radhakrishna Road, Achit Nagar (Post), Soldevanahalli, Bengaluru-560107, India

Uday R., Dr. Manjunatha P. M., Nageena Taj, Nikhil H. R., Rajesh A., Emerging Frontiers in Lung Cancer Management: Targeted Therapy, Immunotherapy, and AI-Driven Innovations, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 3, 105--127. https://doi.org/10.5281/zenodo.18850209

More related articles
Development and Validation of a Rapid RP-HPLC Meth...
Ankita Dhiware, Dr. V. L. Badgujar, Dr. R. D. Wagh, ...
Development And Evaluation of Proliposome Powder f...
Ashwini Khangan, Vaibhav Changediya, ...
A Brief Review On Indian Pharmaceuticals: A Formul...
Rupali V. Nirmal, Nilesh S. Pendbhaje, Anjali Jadhav, Kirti P. Ga...
View more
Comparative Study of Marketed Branded and Generic Metformin Hydrochloride Tablet...
Priyanka Sanjay Ahire , Preeti Bapu Aher , Tufail Dana Shakeel Ahamad, Manohar Baburao Nikam, ...
Evaluation Of The Hepatoprotective Effect Of Nagaradi Kashayam (Amruthotharam) I...
Stephy George, Shifila A. N., ...
Bridelia Montana Wild.: An Ethnomedicinal Plant Advancing Toward Evidence-Based ...
Akansha Ramteke, Dipali Zode, Snehal Sidham, Rajendra Ganjiwale, Deorao Awari, ...
View more
Download PDF
Related Articles
Design and Evaluation of Furosemide Matrix Tablets Using Solid Dispersion Techni...
Dr. Ashish Sarkar, Ankit Kumar, Dr. Afrin Alam, ...
What Are Vaccines and Pharmacovigilance in Vaccine Safety...
Shraddha Magdum , Sonal kumbhar, Dr. Nilesh chougule, ...
Thyroid Study in Patients ...
Gayatri Apotikar, Shubham Tikait, Swati Deshmukh, ...
Effects of a Cognitive Ergonomics Workplace Intervention on Cognitive Strain and...
Sibongile Ngomane, ...
Development and Validation of a Rapid RP-HPLC Method for the Analysis of Afatini...
Ankita Dhiware, Dr. V. L. Badgujar, Dr. R. D. Wagh, ...
More related articles
Development and Validation of a Rapid RP-HPLC Method for the Analysis of Afatini...
Ankita Dhiware, Dr. V. L. Badgujar, Dr. R. D. Wagh, ...
Development And Evaluation of Proliposome Powder for Enhanced Delivery of Deflaz...
Ashwini Khangan, Vaibhav Changediya, ...
A Brief Review On Indian Pharmaceuticals: A Formula For Success...
Rupali V. Nirmal, Nilesh S. Pendbhaje, Anjali Jadhav, Kirti P. Gandhi, ...
View more
Development and Validation of a Rapid RP-HPLC Method for the Analysis of Afatini...
Ankita Dhiware, Dr. V. L. Badgujar, Dr. R. D. Wagh, ...
Development And Evaluation of Proliposome Powder for Enhanced Delivery of Deflaz...
Ashwini Khangan, Vaibhav Changediya, ...
A Brief Review On Indian Pharmaceuticals: A Formula For Success...
Rupali V. Nirmal, Nilesh S. Pendbhaje, Anjali Jadhav, Kirti P. Gandhi, ...
View more

Copyright © 2025 IJPS. All rights reserved